Bioengineering & MedTtech against cancer To meet the challenges in healthcare of the 21st century, it is important to combined bioengineering and MedTech to develop biological system analyze and treatment to treat specifically cancer cells and protect the rest of the patient’s body by limiting side effects. To accomplish…
Emmanuelle Charpentier and Jennifer Doudna have been awarded the Nobel Prize in Chemistry 2020 for discovering a gene technology in Bioengineering: the CRISPR/Cas9 genetic scissors. The announcement marks the first time a science Nobel has been awarded to two women.
Yesterday took place the kick-off meeting of the european project MAD-CoV 2, in which participates the group led by ICREA Research Professor Núria Montserrat at IBEC.
Under the name of “Modern approaches for developing antivirals against SARS-CoV 2” (MAD-CoV 2) the project focuses on the development and delivery of therapeutic tools for the current COVID-19 outbreak.
IBEC contributes to elucidate how the rigidity of the tumor extracellular matrix affects the aggressiveness of neuroblastoma, a cancerous tumor that affects mainly children. This opens the door to generate more accurate models to predict tumor development in patients and to work in the design of new treatments.
Neuroblastoma is the most frequent malignant tumor in the first year of life. It is caused by a genetic mutation from immature nerve cells (neuroblasts) that the fetus produces as part of its development process.
The Molecular and cellular neurobiotechnology group with the collaboration of the Nanobioengineering group, both of them at IBEC, have applied a new light-stimulated technique to modulate muscular activity and stimulate cell regeneration of the peripheral nervous system.
Thanks to this research they have discovered that muscle activity can activate the neurons and accelerate their regeneration after an injury.
The Biosensors for bioengineering group led by Javier Ramón has developed a sensing platform for the in-situ detection of tissue-secreted pro-inflammatory molecules, the so-called cytokines. This new methodology opens a new door in the understanding of metabolic-disorders such those found in muscular diseases, as well as the development of drug-screening applications.
Although 40% of total body mass is skeletal muscle tissue, there is no specialized clinical doctor for the treatment of muscular diseases, according to the American Medical Association. The research group of Dr. Javier Ramón at IBEC works to fill this gap between muscle disorders and ad hoc therapies.
Researchers at IBEC and their collaborators at the Centre of Regenerative Medicine of Barcelona (CMR[B]) have developed a revolutionary new technique based on photoactivation (light activation), by which cells in deep tissue can activated and tracked in vivo without causing any damage.
Manipulating protein expression to monitor cell behavior is a powerful tool in the field of biology.